These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 15558796)

  • 1. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
    Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
    Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
    Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Sagona A; Farante G; Galimberti V; Luini A; Veronesi P; Bonanni B
    Ann Surg Oncol; 2009 Dec; 16(12):3380-7. PubMed ID: 19649554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
    Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
    Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
    Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
    Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma.
    Zablotska LB; Neugut AI
    Cancer; 2003 Mar; 97(6):1404-11. PubMed ID: 12627503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
    Armes JE; Egan AJ; Southey MC; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer; 1998 Dec; 83(11):2335-45. PubMed ID: 9840533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma.
    Kroman N; Holtveg H; Wohlfahrt J; Jensen MB; Mouridsen HT; Blichert-Toft M; Melbye M
    Cancer; 2004 Feb; 100(4):688-93. PubMed ID: 14770422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
    Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
    Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
    Poggi MM; Danforth DN; Sciuto LC; Smith SL; Steinberg SM; Liewehr DJ; Menard C; Lippman ME; Lichter AS; Altemus RM
    Cancer; 2003 Aug; 98(4):697-702. PubMed ID: 12910512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
    Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
    Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.